Localization and variation of TRAIL and its receptors in human placenta during gestation

被引:31
作者
Chen, LH
Liu, XS
Zhu, Y
Cao, YX
Sun, L
Jin, BQ [1 ]
机构
[1] Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China
[2] Fourth Mil Med Univ, Dept Histol & Embryol, Xian 710032, Peoples R China
关键词
TRAIL/TRAILR; human placenta; gestation; immunohistochemistry;
D O I
10.1016/j.lfs.2003.07.044
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The localization of TRAIL and its receptors in human placenta was studied under light microscopy using immunohistochemistry method. The variation of TRAIL and its receptors with development was also detected by in situ semi-quantification. The syncytiotrophoblast, cytotrophoblast, stromal cells and the capillary endothelium cells in human placenta all appeared to be TRAIL immunoreactive and the immunoreactive material was distributed on membrane and in cytoplasm with negative nuclei. During whole gestation there was no obvious variation of the staining of TRAIL. Although DR4, DR5, DcR1 and DcR2 can also be detected in the placenta throughout pregnancy, DR4 and DR5 staining increased with development whereas DcR1 and DcR2 staining decreased. Interestingly, at the beginning of the gestation DR4 and DR5 staining distributed on the cytotrophoblast mainly, whereas DcR1 and DcR2 mainly located in the syncytiotrophoblast cells. Collectively, these results suggest that human placenta may not only produce TRAIL but also be a TRAIL target organ, and that TRAIL/TRAILR system could take part in the self-homeostasis of placenta during whole gestation. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:1479 / 1486
页数:8
相关论文
共 22 条
[1]   Th1-and Th2-type lymphokine-assisted induction and release of chemokine receptors from primary human trophoblast cells [J].
Athanassakis, I ;
Papadimitriou, L ;
Koumantakis, E ;
Vassiliadis, S .
HUMAN IMMUNOLOGY, 2000, 61 (07) :651-657
[2]   DECAY-ACCELERATING FACTOR PROTECTS HUMAN TROPHOBLAST FROM COMPLEMENT-MEDIATED ATTACK [J].
CUNNINGHAM, DS ;
TICHENOR, JR .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 74 (02) :156-161
[3]  
Dealtry GB, 1998, AM J REPROD IMMUNOL, V40, P283
[4]   The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820
[5]   Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL [J].
Emery, JG ;
McDonnell, P ;
Burke, MB ;
Deen, KC ;
Lyn, S ;
Silverman, C ;
Dul, E ;
Appelbaum, ER ;
Eichman, C ;
DiPrinzio, R ;
Dodds, RA ;
James, IE ;
Rosenberg, M ;
Lee, JC ;
Young, PR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) :14363-14367
[6]  
GOLSTEIN P, 1997, CURR BIOL, V7, P750
[7]  
Hammer A, 1999, AM J REPROD IMMUNOL, V42, P88
[8]   COMPLEMENT REGULATORY PROTEINS AT THE FETOMATERNAL INTERFACE DURING HUMAN PLACENTAL DEVELOPMENT - DISTRIBUTION OF CD59 BY COMPARISON WITH MEMBRANE COFACTOR PROTEIN (CD46) AND DECAY ACCELERATING FACTOR (CD55) [J].
HOLMES, CH ;
SIMPSON, KL ;
OKADA, H ;
OKADA, N ;
WAINWRIGHT, SD ;
PURCELL, DFJ ;
HOULIHAN, JM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (06) :1579-1585
[9]  
HUNT JS, 1996, HLA MATERNAL FETAL R, P27
[10]   The TNF and TNF receptor superfamilies: Integrating mammalian biology [J].
Locksley, RM ;
Killeen, N ;
Lenardo, MJ .
CELL, 2001, 104 (04) :487-501